When: Remaining position approaches $365-375 range (~2-3x ATR)

Then: Exit remaining position

Hold core position; trim modestly if overweight (closer to one-third than one-half); do not initiate new short exposure; use put spreads for tail risk below 340; set re-entry triggers at 401.27 daily close on above-average volume with MACD above zero.

• Q2 2026 fundamentals remain strong: revenue +18.5% YoY, gross margin +150 bps, operating margin +310 bps, EPS +26.5%, record FCF of $948M, and $320M buyback in same quarter
• ISRG balance sheet provides structural support: zero long-term debt, $8.6B cash, current ratio nearly 5, three consecutive years of margin expansion
• GLP-1/bariatric headwind is a fraction of procedure mix; procedure mix shifting toward higher-acuity general surgery and gynecologic oncology
• Competitive threats (J&J Ottava, Medtronic Hugo) are multi-year structural risks, not near-term catalysts; installed base and razor-and-blade model create switching cost moat
• Aggressive plan to sell at 50 SMA ($385.80) assumes market cooperates; if price chops sideways between $360-$380, trader misses potential move to 200 SMA at $470
• Conservative risk management reduces exposure modestly, hedges tail with put protection, preserves core long exposure, and waits for next quarter's fundamentals to confirm or reverse bearish thesis

→ vs aggressive: Aggressive thesis conflates technical breakdown with fundamental breakdown; Q2 2026 delivered record FCF and margin expansion in same quarter as technical deterioration, suggesting the tape is not a leading indicator of business deterioration

→ vs aggressive: Argument that 'anyone can hold a great company' is rhetorical flourish, not risk analysis; holding high-quality compounders IS the conservative strategy, and ISRG's balance sheet creates a downside floor the chart cannot see

→ vs aggressive: GLP-1 narrative is overweighted as a thesis-breaker; bariatric is a fraction of procedure mix and management has transparently shifted toward higher-acuity procedures backed by three straight years of margin widening

→ vs aggressive: J&J Ottava and Medtronic Hugo are long-dated structural risks, not quarter-to-quarter catalysts; treating them as near-term drivers misapplies a long-term framework to short-term timing

→ vs aggressive: 'Wait for next leg lower' plan assumes a specific bearish price path; pre-committing to outcomes at levels like 351, 345, or 328 requires knowing which scenario materializes and when, which is market timing conservative risk management aims to prevent

→ vs aggressive: Shorting a 1.46 beta compounder pays up for volatility unnecessarily; put spreads below 340 cost a fraction of short position capital while preserving upside participation

TRIM TO ~80% BENCHMARK WEIGHT; HEDGE WITH PUT SPREADS BELOW 340; RE-ENTER ON CLOSE ABOVE 401.27 WITH MACD CROSSING ABOVE ZERO

• Technical picture shows confirmed bearish stack on all timeframes with MACD bearish cross from plus 0.49 to minus 1.32 in single session, accelerating 200 SMA slope, and 14% July gap-down never recovered
• Q2 2026 fundamentals show record FCF of $948 million, 18.5% YoY revenue growth, 150 bps gross margin expansion, 310 bps operating margin expansion, 26.5% EPS growth
• Balance sheet is fortress with zero LT debt, $8.6 billion cash, current ratio nearly 5, three consecutive years of margin expansion, high switching cost recurring revenue
• Beta of 1.46 and 42x trailing P/E make stock vulnerable in higher for longer rates regime
• Business shifting from bariatric toward higher acuity general surgery and gynecologic oncology; GLP-1 and J&J/Medtronic competitive threats are multi-year stories, not quarter-to-quarter catalysts
• Recommended trim is 20-25% to ~80% benchmark weight, not trader's proposed 33-50% or conservative's full weight
• Execution at 50 SMA of 385.80 should include willingness to market execute if price stuck between 360-380 for 2-3 weeks with MACD failing to recover
• Hedging with 3-6 month put spreads below 340 serves as portfolio insurance, not directional bet
• Re-entry triggers: daily close above 401.27 on above average volume with MACD crossing back above zero

→ vs aggressive: Treating technical breakdown as confirmed fundamental deterioration is overreach; Q2 2026 record FCF of $948M, 18.5% revenue growth, 26.5% EPS growth contradict price-implied deterioration narrative

→ vs aggressive: Overweighting GLP-1 bariatric narrative and slow-moving J&J/Medtronic competitive threats as near-term catalysts when management has transparently shifted toward higher acuity general surgery and gynecologic oncology

→ vs aggressive: Waiting for next leg lower like it's inevitable; it's a probability not certainty and execution dependency at 50 SMA of 385.80 risks missing trim entirely

→ vs conservative: A 38% drawdown from 603 to 375 is not a wobble; treating it as noise while ignoring confirmed death cross regime, unrecovered 14% gap-down, and fresh MACD bearish cross is denial, not conservative risk management

→ vs conservative: Even with perfect fundamentals, multiple compression in higher for longer rates regime can pin stock down for quarters while business keeps compounding; asking to hold full position while chart signals structural change ignores real risk

→ vs conservative: Pre-committing to full weight without explicit technical re-entry rules is building a plan around assumed tape behavior rather than rule-based discipline